Unsere Publikationen

Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis

Link
https://doi.org/10.1016/j.msard.2019.101503
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Lau AY, Lui GCY, Chan K-, Au C, Mok VCT, Ziemssen T.
Verlag
Mult Scler Relat Disord 2020;38.
Zum Eintrag

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study

Link
https://doi.org/10.1007/s40263-020-00700-0
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Naismith RT, Wundes A, Ziemssen T, Jasinska E, Freedman MS, Lembo AJ, Selmaj K, Bidollari I, Chen H, Hanna J, Leigh-Pemberton R, Lopez-Bresnahan M, Lyons J, Miller C, Rezendes D, Wolinsky JS; EVOLVE-MS-2 Study Group.
Verlag
CNS Drugs. 2020 Feb;34(2):185-196.
Zum Eintrag

Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - The CONFIDENCE study protocol

Link
https://doi.org/10.1186/s12883-020-01667-7
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Dirks P, Zingler V, Leemhuis J, Berthold H, Hieke-Schulz S, Wormser D, Ziemssen T.
Verlag
BMC Neurol. 2020 Mar 14;20(1):95.
Zum Eintrag

Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab

Link
https://doi.org/10.1016/j.msard.2019.101893
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Cornelissen C, Ettle B; PANGAEA Study Group.
Verlag
Mult Scler Relat Disord. 2020 Apr;39:101893.
Zum Eintrag

Letter to the editor regarding “Therapeutic drug monitoring of natalizumab”

Link
https://doi.org/10.1177/1352458519837702
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Proschmann U, Sehr T, Akgün K, Ziemssen T.
Verlag
Mult Scler J 2020;26(6):741-742.
Zum Eintrag

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration

Link
https://doi.org/10.3389/fneur.2020.00391
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Sehr T, Akgün K, Haase R, Ziemssen T.
Verlag
Front Neurol 2020;11.
Zum Eintrag

Gaining first insights on secondary progressive multiple sclerosis patients treated with siponimod in clinical routine: Protocol of the noninterventional study Amasia

Link
https://doi.org/10.2196/19598
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Ziemssen T, Hoffmann O, Klotz L, Schreiber H, Weber MS, Rauser B.
Verlag
JMIR Res Prot 2020;9(7).
Zum Eintrag

A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose—Possible Predictors of Cardiac Outcomes

Link
https://doi.org/10.3389/fneur.2020.00818
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Limmroth V, Ziemssen T, Kleiter I, Wagner B, Schmidt S, Lassek C, Baier-Ebert M, Wendt G, Dechend R, Haverkamp W.
Verlag
Front Neurol. 2020 Aug 12;11:818.
Zum Eintrag
6 7 8 9 10

Publikationen durchsuchen

Publikationen filtern

Filters
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Show AllHide
Jahr
-